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s 14 (2015) 3–5Journal of Cystic FibrosiNews0.1. CF foundation honors four for work on hypertonic saline
The Richard C. Talamo Distinguished Clinical Achieve-
ment Award, which recognizes individuals who have spent
their careers researching and caring for people with CF and
whose contributions have made a significant difference in
the lives of people with CF, was presented at the 2014
North American Cystic Fibrosis Conference to Mark R.
Elkins, Ph.D. (Australia), Peter T. P. Bye, M.D. (Australia),
William D. Bennett, Ph.D. (USA), and Scott H. Donaldson,
M.D. (USA). The four were recognized for their important
roles in the development of hypertonic saline, which has
become a standard of care in the treatment of CF lung
disease.0.2. Early respiratory infection is associated with reduced
spirometry in children with cystic fibrosis
Early infection with pro-inflammatory pathogens in BAL
fluid in the first 2 years of life is associated with reduced
lung function in young children. This highlights the
importance of early lower respiratory infection and provides
further support for surveillance programs and implementa-
tion of bacterial eradication protocols (Am J Respir Crit Care
Med 2014; in press doi: http://dx.doi.org/10.1164/rccm.
201407-1277OC).0.3. Prevalence of depression and anxiety in patients with cystic
fibrosis and parent caregivers
The International Depression Epidemiological Study
(TIDES) assessed depression and anxiety across 154 CF
centers in Europe and the USA (6088 patients with CF and
4102 parents). Elevated symptoms of depression and anxiety
were found at rates 2–3 times those of community samples.
The authors recommended annual screening of psychological
symptoms for both patients and parents and there are
guidelines developed by the ECFS and CFF (Thorax 2014;
69:1090-1097).http://dx.doi.org/10.1016/j.jcf.2014.11.004
1569-19931. Events in 2015
ECFS 12th Basic Science Conference — 25–28 March,
Albufeira, Portugal
ECFS 38th European CF Conference— 10–13 June, Brussels,
Belgium
29th Annual North American Cystic Fibrosis Conference—
8–10 October, Phoenix, AZ
ERS/ECFS CF Course— 19–21 November, Prague, Czech
Republic
2. People
There are changes of leadership in the clinical trials networks.
Bonnie Ramsey has stepped down as head of Therapeutics
Development Network (TDN). Since its inception in 1998, the
TDN has grown from 7 to the current 77 participating centers.
The TDN has been enormously successful, achieving its
original goals of facilitating clinical studies of new therapies
for patients with CF, protecting patient safety, developing new
outcome measures, and served as a role model of other rare
diseases. Dr. Ramsey's role in leading this program should not
be underestimated. She has successfully negotiated the unique
partnership between the CF Foundation, academia, and industry,
as well as the regulatory agencies. She has developed a strong
infrastructure that provides a streamlined approach to clinical
research, working to overcome bureaucratic barriers as well as
providing the key mentorship to ensure recognition and success
of junior faculty.
The TDN will be in good hands under the co-leadership of
Nicole Mayer Hamblett, Ph.D. and Christopher Goss, M.D.
both from the University of Washington and with considerable
experience at the TDN. Dr. Hamblett has been at the TDN
Coordinating Center for many years where she has overseen
the design and analysis of more than 30 CF clinical studies,
many of which have resulted in important changes to current
standard of care for the management of CF. Her research
interests include novel approaches for trial design and analyses
pertinent to the rare disease setting, and epidemiologic studies
of risk factors for morbidity and mortality in CF. Dr. Goss has
extensive experience in CF clinical trials and a broad background
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4 Newsin pulmonary clinical care, observational clinical trial design and
conduct, biostatistics and in outcomes research. He also chairs the
CF Foundation Patient Registry Committee.
The TDNworks in close partnership with the European Clinical
Trials Network (ECFS-CTN) led by Isabelle Fajac, M.D., Ph.D.,
who is a pulmonologist and a Professor of Physiology. She has
been a member of the ECFS-CTN Executive Committee since its
beginning in 2008 and its Chair since 2012. She works in the adult
CF center of Cochin Hospital in Paris and she is also Head of the
CF Research Laboratory at Paris Descartes University (Sorbonne
Paris Cité, France). Kris De Boeck was the previous chair of
ECFS-CTN from 2009 until 2012. Together, Kris De Boeck
and Isabelle Fajac have developed a thriving organization with
30 centers which has been involved in 31 clinical trials since its
inception. In 2015, Dr Tim Lee (Leeds, UK) will become chair
and navigate a further expansion of the CTN.
3. ECFS Award 2015— call for nominations
The ECFS Award is given annually to honor a person who
has made an outstanding contribution to our basic understand-
ing of cystic fibrosis or to the treatment or care of patients
with cystic fibrosis. The winner of the award will be invited to
present at the Opening Plenary of the annual conference in
Brussels.
You are cordially invited to nominate a candidate for this
award. The deadline for proposals is 16 February 2015. Please
mail your proposal, accompanied by a detailed motivation and
curriculum vitae of the candidate to the ECFS Executive
Director, Christine Dubois (christine.dubois@ecfs.eu).
4. Gerd Döring Award— call for nominations
The Gerd Döring Award is a new initiative of the European
Cystic Fibrosis Society and will be given annually to honor an
exceptional early career young European scientist. The award,
a monetary donation of 5000 EUR to support research, will
be presented at the Opening Plenary of the annual ECFS
conference in Brussels.
The award will be judged primarily (80%) on a paper
published in the previous 3 calendar years (2012–2014) which
has made a significant impact on the understanding or treatment
of cystic fibrosis. Personal motivation and CV will make a 20%
contribution to the scoring.
The award is open to Ph.D. students and post-doctoral
researchers with up to a maximum of four years academic
research experience following the completion of their Ph.D., or
be of equivalent professional standing at the date of publication
of the paper.
We encourage mentors, supervisors and co-workers of
today's most exceptional early career European scientists to
send in nominations for this competition. Self-nomination is
also encouraged. The deadline for proposals is 16 February
2015. Please mail your proposal, accompanied by a detailed
motivation, a PDF of the nominated paper and curriculum vitae
of the candidate to the ECFS Executive Director, Christine
Dubois (christine.dubois@ecfs.eu).
Nicole Mayer Hamblett Isabelle Fajac
5News
